NanoPUTTY
Commercial- Indications
- Bone regeneration
Company intelligence / Profile preview
NanoFUSE Biologics developed and commercialized the first FDA-approved combination of synthetic bioactive ceramic (45S5 bioglass) with demineralized bone matrix. Clinical data support its efficacy for spinal fusion and orthopedic bone healing, showing rapid formation of hydroxyapatite scaffolds that promote new bone growth within 24 hours. The product is anti-microbial, moldable, customizable, has a five-year shelf life, and is available in multiple forms. It has been used successfully in clinical practice for several years.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NanoFUSE Biologics.